Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
funds
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,741.90 | 26.70 | -0.30% |
CAC 40 | 7,778.34 | 11.93 | -0.15% |
DAX 40 | 24,233.88 | 89.70 | -0.37% |
Dow JONES (US) | 42,319.74 | 108.00 | -0.25% |
FTSE 100 | 8,829.00 | 17.96 | 0.20% |
HKSE | 23,822.44 | 84.53 | -0.35% |
NASDAQ | 19,298.45 | 162.04 | -0.83% |
Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
S&P 500 | 5,939.30 | 31.51 | -0.53% |
S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
SSE Composite Index | 3,385.36 | 1.26 | 0.04% |